Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

NCT ID: NCT01171729

Last Updated: 2010-08-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2010-05-31

Brief Summary

This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.

Detailed Description

CreaVax-PC consisted of antigen (PSA, PAP and KLH) primed dendritic cell is an investigational product designed to activate a man's immune response, so they can detect prostate cancer cells and initiate an immune response against prostate cancer antigens.

If patients decide to participate and are eligible, they will be enrolled in the study and will receive active product (CreaVax-PC). In detail, patients will receive CreaVax-PC injection at intervals of 3 weeks, maximum 6 times during 21 weeks. PSA increase rate is a primary evaluation variables and tumor suppression effect is secondary evaluation variables. We also evaluate time to progression, overall survival and immune response.

Conditions

Prostatic Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Autologous dendritic cell

Autologous dendritic cells pulsed with prostate cancer antigen and KLH

Intervention Type: BIOLOGICAL

Other Intervention Names

CreaVax-PC

Eligibility Criteria

Inclusion Criteria

• 1) Histological confirmed prostatic carcinoma patient
• 2) Hormone non-respondence ex1) Although treatment PSA ≥ 5ng/ml ex2) PSA level were measured two times ex3) Prior one year radiology were processed
• 3) Just 18 years over
• 4) Has a score ≤1 on the ECOG Performance Scale
• 5) Expected survival life time ≥ 6month
• 6) Adequate bone marrow function hemoglobin ≥ 10.0g/dL , leukocyte count ≥ 4,000/mm3 thrombocyte ≥ 100,000/mm3
• 7) Adequate blood coagulation function PT(INR) < 1.5, aPTT< 1.5 x control
• 8) Adequate kidney function Normal blood upper level Creatinine ≤ 1.5 times
• 9) Adequate liver function Normal blood upper level AST/ALT ≤ 1.5 times
• 10) Autoimmune antibody system don't have disorder ex) anti-nuclear antibody, anti-thyroglobulin antibody negativity
• 11) Person who didn't treat prior 6 weeks operation, radiotherapy treatment,immunotherapy or chemotherapy
• 12) Patient who voluntarily participated clinical trial and confirmed a written consent

Exclusion Criteria

• 1) Having other malignancy or previous history of malignancy
• 2) Brain metastases patient
• 3) Having autoimmune disease or its history
• 4) Pyrexia, rigor, leukocytosis infectious disease
• 5) HBsAg, anti-HCV, HIV positive patient
• 6) Myocardial infarction, cardiac insufficiency, other severe heart disease and non-controlled hypertension
• 7) Severe and active medical disease
• 8) Mental history disease or epilepsy
• 9) Patients participated other clinical trial within 4 weeks
• 10) Patients impossible to participate this trial by investigator's decision
• 11) Patients who received immunosuppressant such as steroid, cyclosporin A, azathioprine within 6 weeks

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Center, Korea

OTHER_GOV

Sponsor Role: collaborator

Samsung Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Samsung Medical Center

Principal Investigators

J C W, M.D,Ph.D

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center

Locations

National Cancer Center

Gyeonggi-do, 323 Ilsan-ro Ilsandong-gu Goyang-si, South Korea

Samsung Medical Center

Seoul, Gangnam-Gu, Ilwon-Dong, South Korea

Countries

South Korea

Other Identifiers

2006-10-030

Identifier Type: -

Identifier Source: org_study_id